Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Symptomatic rebound methaemoglobinaemia after treatment with dapsone.
Neth J Med
September 2020
Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
A 28-year-old female patient was admitted to our hospital with severe dyspnoea and hypoxemia due to methaemoglobinaemia caused by dapsone. The patient recovered completely after repeated infusions of methylene blue and cessation of dapsone. However, 12 days after cessation of dapsone, the patient was readmitted due to recurrence of symptoms based on a relapse of methaemoglobinaemia.
View Article and Find Full Text PDFAlteration of intracellular histamine H2 receptor cycling precedes antagonist-induced upregulation.
Am J Physiol Gastrointest Liver Physiol
November 2005
First Dept. of Medicine, Hamamatsu Univ. School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan.
Long-term administration of a histamine H2 receptor (H2R) antagonist (inverse agonist) induces upregulation of H2R in parietal cells, which may be relevant to the rebound hypersecretion of gastric acid that occurs after withdrawal of treatment. The mechanisms underlying this effect are unknown. We hypothesized that the H2R upregulation could be related to receptor trafficking and used H2R-green fluorescent protein (H2R-GFP) to test the hypothesis.
View Article and Find Full Text PDFClinically important drug interactions with zopiclone, zolpidem and zaleplon.
CNS Drugs
July 2003
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdrawal and dependency. The newer hypnosedatives include zolpidem, zaleplon and zopiclone.
View Article and Find Full Text PDFCimetidine treatment for recurrent respiratory papillomatosis.
Int J Pediatr Otorhinolaryngol
December 1999
Department of Paediatric Otolaryngology, Great Ormond Street Hospital for Children, London, UK.
Effective adjuvant treatment for recurrent respiratory papillomatosis (RRP) is at present limited to alpha-interferon, which may have significant side effects including rebound growth of papillomata following its withdrawal, is given by injection and is expensive. High dose cimetidine is known to have immunomodulatory side effects and has been reported as a useful treatment for cutaneous warts. We report a case of very advanced RRP with tracheo-bronchial-pulmonary involvement treated with adjuvant cimetidine at a dose of 40 mg/kg for 4 months.
View Article and Find Full Text PDFClinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications.
Clin Pharmacokinet
September 1995
Clinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Zolpidem is an imidazopyridine which differs in structure from the benzodiazepines and zopiclone. It is a strong sedative with only minor anxiolytic, myorelaxant and anticonvulsant properties, and has been shown to be effective in inducing and maintaining sleep in adults. The available evidence suggests that zolpidem produces no rebound or withdrawal effects, and patients have experienced good daytime alertness.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!